Picture [iito] Made Without Love 650x80px
Document › Details

Bactevo Ltd.. (1/25/17). "Press Release: Bactevo Wins Innovate Award". Cambridge.

Region Region United Kingdom (GB)
Organisations Organisation Bactevo Ltd.
  Today Nanna Therapeutics Ltd.
  Group Astellas (Group)
  Organisation 2 Innovate UK
  Group United Kingdom (GB) (govt)
Products Product antibiotic
  Product 2 business development (state/region)
Index term Index term Bactevo–United Kingdom (govt): grant, 201701 Biomedical Catalyst grant £1.5m from Innovate UK
Person Person Williams, David (Nanna Therapeutics 202004 CEO before Discuva)

Bactevo, the revolutionary Cambridge, UK-based drug discovery company has received an Innovate Award for a prestigious £1.5M grant. Exploiting revolutionary work in the field of integrated, accelerated drug discovery in micro-droplets, Bactevo will progress its programmes focused on generating new antibiotic drugs to highly drug resistant Gram-negative pathogens causing septicaemia, chest and serious urinary tract infections. The Biomedical Catalyst early-stage award is run by the UK’s innovation agency, Innovate UK, recognising Britain’s most innovative, cutting-edge young companies.

David Williams, Bactevo CEO said: “We are pleased to receive this prestigious recognition with a major award from Innovate UK, which will allow us to make a substantial contribution to reducing bacterial infection, currently having a profound effect on our healthcare systems. This is the first announcement on our therapeutic strategy and we will continue to add news on other active disease in due course, as we apply our revolutionary technology platform in other areas of unmet medical need.”

About Bactevo

Bactevo is a Cambridge, UK-based drug discovery company focused on providing new and transformative medicines for poorly addressed or untreatable diseases. Key to Bactevo’s success are a core set of proprietary technologies which give rapid and almost infinite chemistry capabilities and the ability to find leads using small amounts of patient-derived cells or tissue. These technologies use patented intellectual property in ultra-high throughput microfluidic synthetic chemistry, microbiome-derived small molecules, microfluidic screening and machine learning to increase the productivity of drug discovery by 1000-fold. Bactevo believes these capabilities will ultimately result in quicker cheaper and more effective drugs for patients.

For further information please contact:

David Williams, Chief Executive Officer
Tel: +44(0)1223 423506

About Innovate UK

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit

Record changed: 2020-05-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for Astellas (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top